EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines

Raju Sunagar iD, Amit Singh, Sudeep Kumar

Vaccines · 15.04.2023 · 11 (4) · 849

DOI: 10.3390/vaccines11040849 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 15.04.2023. Verfasst von Raju Sunagar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ella Foundation, Hyderabad 500078, India. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global rollout of COVID-19 vaccines has played a critical role in reducing pandemic spread, disease severity, hospitalizations, and deaths. However, the first-generation vaccines failed to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and transmission, partially due to the limited induction of mucosal immunity, leading to the continuous emergence of variants of concern (VOC) and breakthrough infections. To meet the challenges from VOC, limited durability, and lack of mucosal immune response of first-generation vaccines, novel approaches are being investigated. Herein, we have discussed the current knowledge pertaining to natural and vaccine-induced immunity, and the role of the mucosal immune response in controlling SARS-CoV2 infection. We have also presented the current status of the novel approaches aimed at eliciting both mucosal and systemic immunity. Finally, we have presented a novel adjuvant-free approach to elicit effective mucosal immunity against SARS-CoV-2, which lacks the safety concerns associated with live-attenuated vaccine platforms.

Schlagwörter

Stichwörter der Autor:innen

APC targetingCOVID-19SARS-CoV-2adjuvanthuman FcγRIimmunityintranasal vaccinemucosal vaccine

Autor:innen und Institutionen

  • Ella Foundation, Hyderabad 500078, India.
  • Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA.

ORCID-Profile: Raju Sunagar

Förderung

  • United States Department of Defense

Zitieren

APA

Sunagar, R., Singh, A., & Kumar, S. (2023). SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. Vaccines, 11(4), 849. https://doi.org/10.3390/vaccines11040849

Vancouver

Sunagar R, Singh A, Kumar S. SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. Vaccines. 2023;11(4):849. doi:10.3390/vaccines11040849

BibTeX
@article{Sunagar2023,
  author = {Sunagar, Raju and Singh, Amit and Kumar, Sudeep},
  title = {SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines},
  journal = {Vaccines},
  year = {2023},
  volume = {11},
  number = {4},
  pages = {849},
  doi = {10.3390/vaccines11040849}
}
Kostenlos starten →